Navidea Biopharmaceuticals, Inc. (NYSE: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases, with an initial focus on personalized Rheumatoid Arthritis diagnostics. The company, founded in 1983, maintains headquarters in Dublin, Ohio.
Location: United States, Ohio, Dublin
Employees: 11-50
Phone: +1 614-793-7500
Total raised: $60M
Investors 2
| Date | Name | Website |
| - | Hercules C... | htgc.com |
| - | CRG | crglp.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.05.2015 | - | $60M | - |
Mentions in press and media 10
| Date | Title | Description |
| 04.02.2022 | Navidea Biopharmaceuticals : Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American - Form 8-K | Navidea Biopharmaceuticals Announces Settlement of Platinum Litigation; Receipt of Noncompliance Notice from NYSE American DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the &qu... |
| 17.12.2021 | Navidea Biopharmaceuticals : Terminates Stock Purchase Agreement - Form 8-K | Navidea Biopharmaceuticals Terminates Stock Purchase Agreement DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of p... |
| 10.12.2021 | Navidea Biopharmaceuticals : Announces Business Update Call and Changes to Board of Directors Composition - Form 8-K | Navidea Biopharmaceuticals Announces Business Update Call and Changes to Board of Directors Composition Conference Call to be held Thursday, December 16, 2021 at 5:00 pm (EST) DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. ... |
| 27.10.2021 | Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin - Form 8-K | Navidea Biopharmaceuticals Announces Resignation of Jed A. Latkin DUBLIN, Ohio-(BUSINESS WIRE)-October 26, 2021-Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on th... |
| 20.09.2021 | Navidea Biopharmaceuticals : Announces Changes to Board of Directors Composition | DUBLIN, Ohio - Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ('Navidea' or the 'Company'), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced that on September 14, 2021, at a... |
| 17.09.2021 | Navidea Biopharmaceuticals : Announces Changes to Board of Directors Composition (Form 8-K) | Navidea Biopharmaceuticals Announces Changes to Board of Directors Composition DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ('Navidea' or the 'Company'), a company focused on the development of preci... |
| 14.05.2015 | Navidea lands $60m for Lymphoseek | Navidea (NYSE:NAVB) is getting a loan of up to $60 million it plans to use to retire debt and spur wider use of its Lymphoseek cancer imaging agent. The money will come from CRG (formerly Capital Royalty LP), which is providing an initial $... |
| 22.08.2013 | Navidea’s Alzheimer’s imaging agent moves into Phase 3 with Siemens deal, SBIR grant | The presence of amyloid plaques in the brain has been considered a hallmark of neurodegenerative disease for years now. So the thought is that being able to see that those plaques are building up would give clinicians a better way to diagno... |
| 13.03.2013 | Cancer: FDA approves Navidea’s Lymphoseek imaging agent | The FDA approved Navidea Biopharmaceuticals’ Lymphoseek radioactive imaging agent, an injectable drug that helps physicians isolate lymph nodes in patients with breast cancer or melanoma. The Lymphoseek approval marks the 1st time in more t... |
| - | Navidea’s Alzheimer’s imaging agent moves into Phase 3 with Siemens deal, SBIR grant | Navidea Biopharmaceuticals (NYSE:NAVB) is getting some financial support from the NIH for its Alzheimer’s diagnostic technology as it advances into Phase 3 development. The National Institute of Aging awarded up to $1.8 million for a late-s... |